By Emzor Pharmaceuticals has announced that its $23 million Active Pharmaceutical Ingredient (API) production facility will commence local production in Q4 2025, marking a significant step toward pharmaceutical self-sufficiency in Nigeria.
Key Highlights
First large-scale API production in Nigeria with government backing, including support from the Ministry of Health and the Presidency.
Aim: Reduce reliance on imported APIs and strengthen local healthcare delivery.
Inflation and forex volatility impact costs, but Emzor is committed to keeping medicines affordable.
Combatting Counterfeit Drugs
Strong distributor partnerships ensure supply chain integrity.
Stable production helps prevent counterfeiters from exploiting shortages.
Economic Challenges & Government Policies
Exchange rate fluctuations tripled costs, but Emzor is absorbing increases to limit price hikes.
New fiscal policies on manufacturing inputs await implementation, delaying relief.
Emzor’s Commitment to Nigeria & Africa
Ensuring over 200 million Nigerians have access to high-quality medicines.
Overcoming challenges like energy costs, supply chain disruptions, and talent drain.
Expansion plans across Africa to boost regional pharmaceutical stability.
Leadership Statements
Dr. Stella Okoli, GMD/Founder: “Government should support local manufacturers. Nigeria is a great nation, and we will continue to thrive.”
Uzoma Ezeoke, Executive Director: “We are not a charity, but healthcare shouldn’t be a privilege. We ask how we can succeed, not why we can’t.”
Emzor remains steadfast in strengthening Nigeria’s pharmaceutical sector, proving resilience amid economic headwinds.
